ABSTRACT
Objective To improve the curative effect of advanced schistosomiasis patients with ascites and HBV infection. Methods A total of 27 advanced schistosomiasis patients with ascites and HBV infection were selected as a trial group and giv?en with anti?HBV treatment and 31 corresponding patients were as the controls and did not received anti?HBV treatment from February 2003 to December 2012. Results The incidence of ascites recurrence spontaneous peritonitis hepatic encephalopa?thy hepatorenal syndrome upper gastrointestinal bleeding and primary liver cancer in the trial group were significantly lower than those in the control group. The detection indexes of liver function renal function and prothrombin time in the trial group were superior to those in the control group. The mortality in the treatment group was also significantly lower than that in the con?trol group. Conclusion The anti?HBV treatment in the advanced schistosomiasis patients with ascites and HBV infection can obviously improve their physical conditions the survival rate and their life qualities.
ABSTRACT
Objective To explore the efficacy,mechanism and safety of silibinin combined with Ruangan pills(a Chinese herbal preparation)in the treatment of schistosomiasis liver fibrosis. Methods A total of 200 patients with schistosomiasis liver fibrosis were randomly divided into a control group and a treatment group,and 100 patients in each group were respectively admin-istered with oral silibinin alone and oral silibinin combined with Ruangan pills,respectively. The curative effects in the two groups were evaluated in 3 months,6 months,9 months and 12 months respectively. Results The common five clinical symptoms of schistosomiasis liver fibrosis patients significantly relieved in the treatment group 12 months after the therapy,and the total effi-ciency reached more than 75%,which were significantly higher than that in the control group. In the treatment group and the con-trol group,there was no improvement in the liver B ultrasonic classification 3 months and 6 months after the therapy(P>0.05);however,in 9 months and 12 months,the liver B ultrasonic classification in the treatment group was better than that in the control group(P<0.05,P<0.01,respectively). For the four serum indexes of liver fibrosis,there was no significant differences between the two groups in 3 months,however,in 6 months,9 months,and 12 months,there was a significant improvement in the treat-ment group compared with the control group. There were no obviously adverse effects in two groups. Conclusion Silibinin com-bined with Ruangan pills has a better curative effect in the treatment of schistosomiasis liver fibrosis.
ABSTRACT
Objective To evaluate the long-term therapeutic effect of Ruangan pills on advanced schistosomiasis combined with ascites. Methods The data of 54 advanced schistosomiasis patients with ascites were collected,and the patients were divid-ed into two groups namely a treatment group and a control group according to whether taking Ruangan pills. The effective rates,im-provement status of symptoms and levels of serum albumin(ALB)and hyaluronic acid(HA)of the two groups were compared. Re-sults The effective rates of the treatment group and control group were 92.59%and 44.44%,respectively,and the difference be-tween them was statistically significant(P<0.05). After the treatment for 9 and 12 months,the percentages of patients without as-cites and patients with symptom improvement in the treatment group were 77.78%and 92.59%,92.59%and 96.30%,respective-ly,while those in the control group were 29.63%and 37.00%,48.15%and 51.85%,respectively,and the differences between the two groups by different time were all statistical significant(all P<0.05). After the treatment for 9 months,the percentages of patients with the normal levels of ALB and HA were 88.89% and 59.26%,while those in the control group were 40.74% and 14.81%,respectively,and the differences between the two groups were statistically significant(both P < 0.05). Conclusion The long-term treatment of Ruangan pills can not only improve clinical symptoms but also control the ascites recurrence,however, the therapeutic effect and the recurrence rate of ascites in longer-term still need further observation.